nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—TACR1—respiratory system—chronic obstructive pulmonary disease	0.0291	0.253	CbGeAlD
Fosaprepitant—TACR1—connective tissue—chronic obstructive pulmonary disease	0.0256	0.223	CbGeAlD
Fosaprepitant—TACR1—smooth muscle tissue—chronic obstructive pulmonary disease	0.0234	0.204	CbGeAlD
Fosaprepitant—TACR1—trachea—chronic obstructive pulmonary disease	0.0215	0.187	CbGeAlD
Fosaprepitant—Aprepitant—CYP1A2—chronic obstructive pulmonary disease	0.0182	1	CrCbGaD
Fosaprepitant—TACR1—lung—chronic obstructive pulmonary disease	0.0154	0.134	CbGeAlD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP12—chronic obstructive pulmonary disease	0.00514	0.092	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide GPCRs—CXCR2—chronic obstructive pulmonary disease	0.00456	0.0817	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.00223	0.0398	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCR2—chronic obstructive pulmonary disease	0.00215	0.0384	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.00201	0.0359	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.00149	0.00183	CcSEcCtD
Fosaprepitant—Cough—Arformoterol—chronic obstructive pulmonary disease	0.00149	0.00183	CcSEcCtD
Fosaprepitant—Cough—Formoterol—chronic obstructive pulmonary disease	0.00149	0.00183	CcSEcCtD
Fosaprepitant—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.00147	0.00182	CcSEcCtD
Fosaprepitant—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.00147	0.00182	CcSEcCtD
Fosaprepitant—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.00147	0.00181	CcSEcCtD
Fosaprepitant—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.00147	0.00181	CcSEcCtD
Fosaprepitant—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00147	0.00181	CcSEcCtD
Fosaprepitant—Cough—Montelukast—chronic obstructive pulmonary disease	0.00146	0.00179	CcSEcCtD
Fosaprepitant—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.00145	0.00179	CcSEcCtD
Fosaprepitant—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.00145	0.00179	CcSEcCtD
Fosaprepitant—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.00145	0.00179	CcSEcCtD
Fosaprepitant—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.00145	0.00179	CcSEcCtD
Fosaprepitant—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.00144	0.00178	CcSEcCtD
Fosaprepitant—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.00144	0.00178	CcSEcCtD
Fosaprepitant—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00144	0.00178	CcSEcCtD
Fosaprepitant—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00144	0.00178	CcSEcCtD
Fosaprepitant—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.00144	0.00178	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	0.00144	0.0258	CbGpPWpGaD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	0.00144	0.00177	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Arformoterol—chronic obstructive pulmonary disease	0.00144	0.00177	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—LEP—chronic obstructive pulmonary disease	0.00143	0.0256	CbGpPWpGaD
Fosaprepitant—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00143	0.00177	CcSEcCtD
Fosaprepitant—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00143	0.00177	CcSEcCtD
Fosaprepitant—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.00142	0.00175	CcSEcCtD
Fosaprepitant—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00142	0.00175	CcSEcCtD
Fosaprepitant—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00142	0.00175	CcSEcCtD
Fosaprepitant—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.00141	0.00174	CcSEcCtD
Fosaprepitant—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00141	0.00174	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.00141	0.00174	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00141	0.00174	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TLR4—chronic obstructive pulmonary disease	0.0014	0.0251	CbGpPWpGaD
Fosaprepitant—Cough—Salbutamol—chronic obstructive pulmonary disease	0.0014	0.00173	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.00139	0.0249	CbGpPWpGaD
Fosaprepitant—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00139	0.00171	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.00139	0.00171	CcSEcCtD
Fosaprepitant—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00139	0.00171	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.00139	0.00171	CcSEcCtD
Fosaprepitant—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00139	0.00171	CcSEcCtD
Fosaprepitant—Infection—Formoterol—chronic obstructive pulmonary disease	0.00138	0.0017	CcSEcCtD
Fosaprepitant—Infection—Arformoterol—chronic obstructive pulmonary disease	0.00138	0.0017	CcSEcCtD
Fosaprepitant—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.00137	0.00169	CcSEcCtD
Fosaprepitant—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.00137	0.00169	CcSEcCtD
Fosaprepitant—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00136	0.00168	CcSEcCtD
Fosaprepitant—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00136	0.00168	CcSEcCtD
Fosaprepitant—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00136	0.00168	CcSEcCtD
Fosaprepitant—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.00136	0.00168	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.00136	0.00168	CcSEcCtD
Fosaprepitant—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00136	0.00168	CcSEcCtD
Fosaprepitant—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00135	0.00167	CcSEcCtD
Fosaprepitant—Infection—Montelukast—chronic obstructive pulmonary disease	0.00135	0.00167	CcSEcCtD
Fosaprepitant—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.00135	0.00166	CcSEcCtD
Fosaprepitant—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00135	0.00166	CcSEcCtD
Fosaprepitant—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00135	0.00166	CcSEcCtD
Fosaprepitant—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00135	0.00166	CcSEcCtD
Fosaprepitant—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00134	0.00165	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—NOS2—chronic obstructive pulmonary disease	0.00133	0.0239	CbGpPWpGaD
Fosaprepitant—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.00133	0.00165	CcSEcCtD
Fosaprepitant—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.00133	0.00164	CcSEcCtD
Fosaprepitant—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.00132	0.00163	CcSEcCtD
Fosaprepitant—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.00132	0.00162	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.00131	0.00162	CcSEcCtD
Fosaprepitant—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00131	0.00162	CcSEcCtD
Fosaprepitant—Infection—Salbutamol—chronic obstructive pulmonary disease	0.0013	0.00161	CcSEcCtD
Fosaprepitant—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.0013	0.0016	CcSEcCtD
Fosaprepitant—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.0013	0.0016	CcSEcCtD
Fosaprepitant—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.00129	0.00159	CcSEcCtD
Fosaprepitant—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00129	0.00159	CcSEcCtD
Fosaprepitant—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.00129	0.00159	CcSEcCtD
Fosaprepitant—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.00129	0.00158	CcSEcCtD
Fosaprepitant—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.00127	0.00157	CcSEcCtD
Fosaprepitant—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.00127	0.00156	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.00127	0.00156	CcSEcCtD
Fosaprepitant—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00126	0.00155	CcSEcCtD
Fosaprepitant—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00126	0.00155	CcSEcCtD
Fosaprepitant—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00125	0.00154	CcSEcCtD
Fosaprepitant—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.00124	0.00153	CcSEcCtD
Fosaprepitant—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.00124	0.00153	CcSEcCtD
Fosaprepitant—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.00124	0.00152	CcSEcCtD
Fosaprepitant—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.00124	0.00152	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.00123	0.0221	CbGpPWpGaD
Fosaprepitant—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.00123	0.00152	CcSEcCtD
Fosaprepitant—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.00123	0.00151	CcSEcCtD
Fosaprepitant—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.00122	0.00151	CcSEcCtD
Fosaprepitant—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.00122	0.00151	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—EDN1—chronic obstructive pulmonary disease	0.00122	0.0218	CbGpPWpGaD
Fosaprepitant—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.00122	0.0015	CcSEcCtD
Fosaprepitant—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.00121	0.00149	CcSEcCtD
Fosaprepitant—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00121	0.00149	CcSEcCtD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—EDN1—chronic obstructive pulmonary disease	0.0012	0.0215	CbGpPWpGaD
Fosaprepitant—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.0012	0.00148	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.0012	0.00148	CcSEcCtD
Fosaprepitant—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.0012	0.00148	CcSEcCtD
Fosaprepitant—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.0012	0.00148	CcSEcCtD
Fosaprepitant—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.0012	0.00148	CcSEcCtD
Fosaprepitant—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00147	CcSEcCtD
Fosaprepitant—Pain—Formoterol—chronic obstructive pulmonary disease	0.00119	0.00147	CcSEcCtD
Fosaprepitant—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00147	CcSEcCtD
Fosaprepitant—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00119	0.00147	CcSEcCtD
Fosaprepitant—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00119	0.00146	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.00117	0.00145	CcSEcCtD
Fosaprepitant—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.00117	0.00145	CcSEcCtD
Fosaprepitant—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.00117	0.00144	CcSEcCtD
Fosaprepitant—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.00117	0.00144	CcSEcCtD
Fosaprepitant—Pain—Montelukast—chronic obstructive pulmonary disease	0.00116	0.00143	CcSEcCtD
Fosaprepitant—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.00116	0.00143	CcSEcCtD
Fosaprepitant—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.00115	0.00142	CcSEcCtD
Fosaprepitant—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00115	0.00142	CcSEcCtD
Fosaprepitant—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00115	0.00142	CcSEcCtD
Fosaprepitant—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.00115	0.00141	CcSEcCtD
Fosaprepitant—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.00141	CcSEcCtD
Fosaprepitant—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.00114	0.00141	CcSEcCtD
Fosaprepitant—Headache—Aminophylline—chronic obstructive pulmonary disease	0.00114	0.00141	CcSEcCtD
Fosaprepitant—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00114	0.00141	CcSEcCtD
Fosaprepitant—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.00114	0.0014	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00114	0.0014	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.0014	CcSEcCtD
Fosaprepitant—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.00114	0.0014	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.00113	0.0014	CcSEcCtD
Fosaprepitant—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00113	0.00139	CcSEcCtD
Fosaprepitant—Pain—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00138	CcSEcCtD
Fosaprepitant—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.00112	0.00138	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00111	0.00137	CcSEcCtD
Fosaprepitant—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	0.00111	0.00137	CcSEcCtD
Fosaprepitant—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.0011	0.00136	CcSEcCtD
Fosaprepitant—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.0011	0.00136	CcSEcCtD
Fosaprepitant—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.0011	0.00135	CcSEcCtD
Fosaprepitant—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.0011	0.00135	CcSEcCtD
Fosaprepitant—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.0011	0.00135	CcSEcCtD
Fosaprepitant—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.0011	0.00135	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.0011	0.0196	CbGpPWpGaD
Fosaprepitant—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.00109	0.00135	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EDN1—chronic obstructive pulmonary disease	0.00109	0.0195	CbGpPWpGaD
Fosaprepitant—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00109	0.00134	CcSEcCtD
Fosaprepitant—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00108	0.00134	CcSEcCtD
Fosaprepitant—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00108	0.00134	CcSEcCtD
Fosaprepitant—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.00108	0.00133	CcSEcCtD
Fosaprepitant—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.00108	0.00133	CcSEcCtD
Fosaprepitant—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00108	0.00133	CcSEcCtD
Fosaprepitant—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.00108	0.00133	CcSEcCtD
Fosaprepitant—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.00108	0.00133	CcSEcCtD
Fosaprepitant—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.00108	0.00133	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00132	CcSEcCtD
Fosaprepitant—TACR1—G alpha (q) signalling events—HTR2A—chronic obstructive pulmonary disease	0.00107	0.0191	CbGpPWpGaD
Fosaprepitant—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00129	CcSEcCtD
Fosaprepitant—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00128	CcSEcCtD
Fosaprepitant—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.00104	0.00128	CcSEcCtD
Fosaprepitant—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.00102	0.00126	CcSEcCtD
Fosaprepitant—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.00102	0.00126	CcSEcCtD
Fosaprepitant—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.00102	0.00126	CcSEcCtD
Fosaprepitant—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.00101	0.00125	CcSEcCtD
Fosaprepitant—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.001	0.00124	CcSEcCtD
Fosaprepitant—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000997	0.00123	CcSEcCtD
Fosaprepitant—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000997	0.00123	CcSEcCtD
Fosaprepitant—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000983	0.00121	CcSEcCtD
Fosaprepitant—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000983	0.00121	CcSEcCtD
Fosaprepitant—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000981	0.00121	CcSEcCtD
Fosaprepitant—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000981	0.00121	CcSEcCtD
Fosaprepitant—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000976	0.0012	CcSEcCtD
Fosaprepitant—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000968	0.00119	CcSEcCtD
Fosaprepitant—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000967	0.00119	CcSEcCtD
Fosaprepitant—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000963	0.00119	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—chronic obstructive pulmonary disease	0.000954	0.0171	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—CXCL8—chronic obstructive pulmonary disease	0.000952	0.017	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000951	0.00117	CcSEcCtD
Fosaprepitant—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000951	0.00117	CcSEcCtD
Fosaprepitant—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000941	0.00116	CcSEcCtD
Fosaprepitant—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000931	0.00115	CcSEcCtD
Fosaprepitant—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000928	0.00114	CcSEcCtD
Fosaprepitant—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.000922	0.00114	CcSEcCtD
Fosaprepitant—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000919	0.00113	CcSEcCtD
Fosaprepitant—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000919	0.00113	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL1B—chronic obstructive pulmonary disease	0.000913	0.0163	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	0.000903	0.0162	CbGpPWpGaD
Fosaprepitant—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.0009	0.00111	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000898	0.0161	CbGpPWpGaD
Fosaprepitant—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000898	0.00111	CcSEcCtD
Fosaprepitant—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000883	0.00109	CcSEcCtD
Fosaprepitant—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000883	0.00109	CcSEcCtD
Fosaprepitant—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000876	0.00108	CcSEcCtD
Fosaprepitant—Rash—Formoterol—chronic obstructive pulmonary disease	0.000876	0.00108	CcSEcCtD
Fosaprepitant—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000875	0.00108	CcSEcCtD
Fosaprepitant—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000875	0.00108	CcSEcCtD
Fosaprepitant—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00087	0.00107	CcSEcCtD
Fosaprepitant—Headache—Formoterol—chronic obstructive pulmonary disease	0.00087	0.00107	CcSEcCtD
Fosaprepitant—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.00087	0.00107	CcSEcCtD
Fosaprepitant—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000868	0.00107	CcSEcCtD
Fosaprepitant—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000865	0.00107	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—MMP9—chronic obstructive pulmonary disease	0.000861	0.0154	CbGpPWpGaD
Fosaprepitant—Rash—Montelukast—chronic obstructive pulmonary disease	0.000858	0.00106	CcSEcCtD
Fosaprepitant—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000857	0.00106	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000855	0.00105	CcSEcCtD
Fosaprepitant—Headache—Montelukast—chronic obstructive pulmonary disease	0.000853	0.00105	CcSEcCtD
Fosaprepitant—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000842	0.00104	CcSEcCtD
Fosaprepitant—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000834	0.00103	CcSEcCtD
Fosaprepitant—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000831	0.00103	CcSEcCtD
Fosaprepitant—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000827	0.00102	CcSEcCtD
Fosaprepitant—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000827	0.00102	CcSEcCtD
Fosaprepitant—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000826	0.00102	CcSEcCtD
Fosaprepitant—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000825	0.00102	CcSEcCtD
Fosaprepitant—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000825	0.00102	CcSEcCtD
Fosaprepitant—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000822	0.00101	CcSEcCtD
Fosaprepitant—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.00081	0.000999	CcSEcCtD
Fosaprepitant—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000808	0.000997	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	0.000807	0.0144	CbGpPWpGaD
Fosaprepitant—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000796	0.000982	CcSEcCtD
Fosaprepitant—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000784	0.000966	CcSEcCtD
Fosaprepitant—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000779	0.000961	CcSEcCtD
Fosaprepitant—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000776	0.000956	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	0.000769	0.0138	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000761	0.0136	CbGpPWpGaD
Fosaprepitant—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000756	0.000933	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000752	0.000928	CcSEcCtD
Fosaprepitant—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000752	0.000928	CcSEcCtD
Fosaprepitant—Shock—Prednisolone—chronic obstructive pulmonary disease	0.00074	0.000913	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.00073	0.0131	CbGpPWpGaD
Fosaprepitant—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000727	0.000897	CcSEcCtD
Fosaprepitant—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000719	0.000887	CcSEcCtD
Fosaprepitant—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000714	0.000881	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TGFB1—chronic obstructive pulmonary disease	0.00071	0.0127	CbGpPWpGaD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	0.000706	0.0126	CbGpPWpGaD
Fosaprepitant—Angiopathy—Prednisone—chronic obstructive pulmonary disease	0.000698	0.000861	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	0.000698	0.0125	CbGpPWpGaD
Fosaprepitant—TACR1—Spinal Cord Injury—EGFR—chronic obstructive pulmonary disease	0.000696	0.0125	CbGpPWpGaD
Fosaprepitant—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000695	0.000857	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	0.000688	0.0123	CbGpPWpGaD
Fosaprepitant—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.000681	0.000839	CcSEcCtD
Fosaprepitant—Mental disorder—Prednisone—chronic obstructive pulmonary disease	0.000674	0.000831	CcSEcCtD
Fosaprepitant—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.00067	0.000826	CcSEcCtD
Fosaprepitant—Erythema—Prednisone—chronic obstructive pulmonary disease	0.00067	0.000826	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TNF—chronic obstructive pulmonary disease	0.000663	0.0119	CbGpPWpGaD
Fosaprepitant—TACR1—Peptide ligand-binding receptors—CXCL8—chronic obstructive pulmonary disease	0.00065	0.0116	CbGpPWpGaD
Fosaprepitant—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000643	0.000793	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000622	0.000767	CcSEcCtD
Fosaprepitant—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.00062	0.000765	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	0.00062	0.0111	CbGpPWpGaD
Fosaprepitant—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000619	0.000764	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000618	0.0111	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	0.000615	0.011	CbGpPWpGaD
Fosaprepitant—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000612	0.000755	CcSEcCtD
Fosaprepitant—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000604	0.000745	CcSEcCtD
Fosaprepitant—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000601	0.000741	CcSEcCtD
Fosaprepitant—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000598	0.000737	CcSEcCtD
Fosaprepitant—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000589	0.000726	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—TP53—chronic obstructive pulmonary disease	0.000584	0.0105	CbGpPWpGaD
Fosaprepitant—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000578	0.000713	CcSEcCtD
Fosaprepitant—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000568	0.000701	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	0.000566	0.000698	CcSEcCtD
Fosaprepitant—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000564	0.000695	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	0.000563	0.0101	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000554	0.000684	CcSEcCtD
Fosaprepitant—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000547	0.000674	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.000547	0.000674	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000544	0.00974	CbGpPWpGaD
Fosaprepitant—Infection—Prednisone—chronic obstructive pulmonary disease	0.000543	0.00067	CcSEcCtD
Fosaprepitant—Shock—Prednisone—chronic obstructive pulmonary disease	0.000538	0.000663	CcSEcCtD
Fosaprepitant—TACR1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	0.000538	0.00962	CbGpPWpGaD
Fosaprepitant—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000536	0.000661	CcSEcCtD
Fosaprepitant—TACR1—Spinal Cord Injury—IL6—chronic obstructive pulmonary disease	0.000535	0.00957	CbGpPWpGaD
Fosaprepitant—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000531	0.000655	CcSEcCtD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.00053	0.00948	CbGpPWpGaD
Fosaprepitant—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000529	0.000652	CcSEcCtD
Fosaprepitant—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000498	0.000614	CcSEcCtD
Fosaprepitant—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000495	0.00061	CcSEcCtD
Fosaprepitant—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000481	0.000593	CcSEcCtD
Fosaprepitant—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000475	0.000586	CcSEcCtD
Fosaprepitant—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000474	0.000585	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000474	0.000584	CcSEcCtD
Fosaprepitant—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000471	0.000581	CcSEcCtD
Fosaprepitant—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000471	0.000581	CcSEcCtD
Fosaprepitant—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000468	0.000577	CcSEcCtD
Fosaprepitant—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000451	0.000556	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000447	0.000551	CcSEcCtD
Fosaprepitant—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000447	0.000551	CcSEcCtD
Fosaprepitant—TACR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	0.000436	0.00781	CbGpPWpGaD
Fosaprepitant—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000434	0.000536	CcSEcCtD
Fosaprepitant—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000432	0.000533	CcSEcCtD
Fosaprepitant—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000432	0.000533	CcSEcCtD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	0.000431	0.0077	CbGpPWpGaD
Fosaprepitant—TACR1—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	0.000428	0.00765	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000412	0.00738	CbGpPWpGaD
Fosaprepitant—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000403	0.000497	CcSEcCtD
Fosaprepitant—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000392	0.000484	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	0.000389	0.00695	CbGpPWpGaD
Fosaprepitant—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000387	0.000477	CcSEcCtD
Fosaprepitant—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000374	0.000461	CcSEcCtD
Fosaprepitant—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000362	0.000446	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	0.000353	0.00632	CbGpPWpGaD
Fosaprepitant—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000348	0.000429	CcSEcCtD
Fosaprepitant—TACR1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	0.000347	0.00621	CbGpPWpGaD
Fosaprepitant—Rash—Prednisone—chronic obstructive pulmonary disease	0.000345	0.000425	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000344	0.000425	CcSEcCtD
Fosaprepitant—Headache—Prednisone—chronic obstructive pulmonary disease	0.000343	0.000422	CcSEcCtD
Fosaprepitant—TACR1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000332	0.00595	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	0.000332	0.00594	CbGpPWpGaD
Fosaprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	0.000331	0.00592	CbGpPWpGaD
Fosaprepitant—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000325	0.0004	CcSEcCtD
Fosaprepitant—TACR1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	0.000315	0.00564	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	0.000304	0.00544	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	0.000276	0.00494	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000243	0.00435	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000226	0.00404	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000209	0.00373	CbGpPWpGaD
Fosaprepitant—TACR1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	0.000188	0.00336	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000186	0.00333	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	0.00017	0.00305	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000169	0.00303	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000163	0.00292	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000152	0.00271	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	0.000125	0.00223	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	0.000119	0.00213	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	0.000114	0.00203	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	0.000101	0.0018	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.58e-05	0.00171	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.11e-05	0.00163	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.18e-05	0.00146	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.51e-05	0.00134	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.36e-05	0.00132	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.18e-05	0.00111	CbGpPWpGaD
Fosaprepitant—TACR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.66e-05	0.00101	CbGpPWpGaD
